Meet Our Oncologists / Hematologists
Dedicated Physicians, Providing The Best Possible Cancer Care
Chief Of Medical Oncology
A. Eli Gabayan, M.D. (Afshin Eli Gabayan, MD)
Medical Director of Beverly Hills Cancer Center
Assistant Clinical Professor - UCLA David Geffen School of Medicine
Dedicated to providing the best available therapies to his patients, Dr. A. Eli Gabayan (Afshin Eli Gabayan) has remained avidly involved in multiple cancer research studies and clinical trials throughout a career that began at the prestigious University of Southern California (USC) School of Medicine.
Dr. Gabayan completed his internship and residency at University of California, Los Angeles (UCLA) where he also served as Chief Resident. He received his Oncology and Hematology training at Cedars-Sinai Medical Center, where he remained as an attending physician in private practice with expertise in the areas of gastrointestinal, lung, breast cancers and multiple myeloma.
Dr. Eli Gabayan tirelessly strives for the best and most current treatments medical science can offer to his patients and their families. This passion for knowledge and education led to Dr. Gabayan's post as an assistant clinical professor at the esteemed David Geffen School of Medicine at UCLA. Firmly committed to the community, Dr. Gabayan maintains strong local ties through his frequent lectures on a wide variety of oncology and hematology topics.
At the heart of Dr. Gabayan's practice is a passionate advocacy for the advancement of medical research for all cancer patients coupled with a vigilant dedication to making the latest therapy and treatment options available to his own patients. Known as among the best medical oncologists & hematologists not only in Los Angeles, but the world Dr. Gabayan believes that knowledge is power and communication is essential to good patient care. As the Chief of Medical Oncology at the Beverly Hills Cancer Center, Dr. A. Eli Gabayan has made it a personal goal to deliver compassionate, yet state of the art care in a healing environment.
Director Of Clinical Research
Steven J. O'Day, M.D.
Director of Los Angeles Skin Cancer Institute at Beverly Hills Cancer Center
Clinical Associate Professor of Medicine - USC Keck School of Medicine
Adjunct Faculty - John Wayne Cancer Institute
Steven J. O'Day, MD is a board-certified medical oncologist at Beverly Hills Cancer Center and has been at the forefront of new drug development in melanoma over the last two decades. He is recognized as one of the preeminent melanoma specialists in the world. Dr. O'Day is a graduate of Williams College with a BA in Chemistry. Following college, he studied medical ethics at Oxford University on a visiting scholars program. He returned to the US to attended medical school at Johns Hopkins and completed his medical internship and residency in Internal Medicine on the Osler Service at Hopkins. He completed his fellowship medical oncology at Dana Farber Cancer Institute at Harvard University, including specialized training in hematologic malignancies and bone marrow transplantation.
Dr. O'Day also completed a Clinical Effectiveness Program at the Harvard School of Public Health. In 1994, after serving as an Attending Physician at Dana Farber, Dr. O'Day came to Los Angeles to found the Medical Oncology Division of The John Wayne Cancer Institute in partnership with the world-class Surgical Oncology Faculty and melanoma experts of The John Wayne Cancer Institute. More recently, he was a founding member of The Angeles Clinic and Research Institute in Santa Monica, California.
Dr. O'Day is recognized as one of the preeminent melanoma specialists in the world, and combines expert clinical care with teaching and leading clinical research. He lectures extensively, both nationally and internationally. His research has focused for many years on the combination of chemotherapy and immunotherapy in the treatment of metastatic melanoma. He has been at the forefront of new drug development in melanoma over the last two decades. His recent research has concentrated on T-cell targeted antibodies, targeted MAPK inhibitors and anti-angiogenesis drugs.
Dr. O'Day has been a principal investigator on over 100 clinical trials including several large, international Phase III trials. He has published more than 200 manuscripts, abstracts and reviews in prestigious journals such as The New England Journal of Medicine (NEJM), Journal of Clinical Oncology (JCO), Blood, Journal of American Medical Association (JAMA), Cancer, Lancet Oncology and the Journal of the National Cancer Institute. He serves on the editorial boards and as a reviewer for many prestigious journals including JCO and Clinical Cancer Research. Dr. O'Day has served on the ASCO Education Committee for melanoma. In addition, he has served on the ASCO International Development and Education Award (IDEA) Working Group where he has served as a mentor for an IDEA grant recipient as well as an IDEA grant reviewer.
As a top medical oncologist and hematologist, over the last two decades, Dr. O'Day has made a significant contribution to melanoma treatment and research in Los Angeles and worldwide, playing key roles in the research that led to the FDA approval of two new drugs (ipilimumab, vemurafenib) for the treatment of metastatic melanoma. Both drugs have demonstrated an overall survival benefit in large, randomized clinical trials. As a result of this work, Dr. O'Day has been a co-author on three recent New England Journal of Medicine papers. Each of these papers has been honored with presentation at ASCO's Plenary sessions, at the 2010 and 2011 meetings. Dr. O'Day was a co-first author on the first of these papers (ipilimumab) and gave the 2010 ASCO Plenary oral presentation. This landmark paper represented the first study to demonstrate improvement in overall survival for patients with refractory metastatic melanoma. The second ipilimumab study confirmed this survival benefit as first line therapy in metastatic melanoma and was presented at the 2011 ASCO Plenary session by co-investigator, Dr. Jedd Wolchuk. The third study demonstrated an improvement in survival with a second drug (vemurafenib), a novel BRAF-targeted oral agent for patients with BRAF-mutated metastatic melanoma. This third paper was presented by co-investigator Dr. Paul Chapman at the 2011 ASCO Plenary session.
Inspired by the recent significant breakthroughs in the treatment of melanoma, Dr. O'Day's remains dedicated to patient care, clinical research and drug development in the treatment of melanoma. He is interested in expanding the success of tumor immunology in melanoma more broadly across oncologic tumors. He is confident that strategic combinational approaches based on high quality translational science, rigorous clinical research design and critical biomarker discovery, will lead to significant new advances in oncology in the coming years.
Linnea I. Chap, M.D.
Hematology/Oncology (Women's Oncology)
Clinical Associate Professor - UCLA School of Medicine
Linnea Chap, MD is a highly respected specialist in breast cancer and gynecologic malignancies and is annually listed as one of "America's Top Doctors for Cancer." She received her B.S. in Chemistry from the University of Illinois and graduated Summa Cum Laude with High Honors. She subsequently received her medical degree from the University of Chicago, Pritzker School of Medicine.
Dr. Chap completed residency in internal medicine at Northwestern Memorial Hospital and fellowships in both hematology and oncology at the UCLA Medical Center.
After her fellowship, she joined the UCLA faculty where she was promoted to Associate Professor of Medicine and was the co-director of the UCLA/Revlon Multidisciplinary Breast Clinic.
Dr. Chap has numerous publications to her credit in highly regarded peer review journals. She has been a leader in the treatment and research of breast and gynecological malignancies and has led several breast and ovarian cancer treatment protocols, including the pioneering use of novel biologic agents such as Herceptin and Avastin.
As among the best medical oncologists and hematologists, Dr. Chap has received several prestigious awards throughout her career. In 2001, she was named one of "America's Top Breast Cancer Doctors" by Redbook, a national women's magazine. Annually, she is listed as one of "America's Top Doctors for Cancer." Recognized for her teaching and speaking skills, Dr. Chap is frequently called upon to relate the most recent advances in breast cancer treatment. In addition to her active involvement with clinical trials and research, she is well-versed in the areas of risk reduction and genetic testing.
U.S. News Media Group recently announced "U.S. News Top Doctors." A highly respected specialist in breast cancer and gynecologic malignancies, Dr. Linnea Chap is listed in this prestigious directory and considered among the top 1% of doctors in the country. Dr. Chap was also listed in Los Angeles Magazine in January 2012, under the listing for Top Doctors in Los Angeles. She has also been selected to Southern California Super Doctors annually, since 2007.
David P. Wu, M.D.
David P. Wu, M.D. is board certified in hematology and oncology. As a renowned oncology specialist, David P. Wu, M.D. believes in compassionate care that focuses on the whole person, instead of just the disease process. Combining the latest treatment modalities, he works with patients to form a comprehensive care plan that suits individual needs, taking into account inherent healing properties of the human body. He believes open communication is vital in this teamwork approach in order to achieve optimal health outcomes.
Dr. David P. Wu is proud to provide patients with state-of-the-art cancer care at the Beverly Hills Cancer Center. Originally from the San Gabriel Valley, Dr. Wu attended Duke University in Durham, North Carolina where he completed a double major in Biomedical and Electrical Engineering. He received his Medical Degree from the University of California San Diego School of Medicine in La Jolla, California.
After graduating from medical school, Dr. Wu completed Residency in Internal Medicine at Yale New Haven Hospital. Following residency, he completed fellowship in Hematology and Oncology at Columbia Presbyterian Hospital in New York, New York.
While he is able to provide the latest treatments for all types of cancer, Dr. Wu has a special interest in the treatment of liver, colorectal and gastrointestinal cancer. He is fluent in Mandarin Chinese which is his primary language.
Schedule a Consultation Today!
Your health is important, and we welcome the opportunity to help you heal.
To schedule an appointment, please call Beverly Hills Cancer Center in Beverly Hills, California at (877) 351-0088 or use our interactive Online Appointment Request Form.
- Medical Oncology
- Radiation Oncology
- Diagnostic Reference Lab
- In-House Pharmacy
- Los Angeles Skin Cancer Institute
- Concierge Medical Services
- International Patients
- Integrative Care Services